Sales & Marketing Closed & Collaborative H1 2025: Mergers, acquisitions, colla... The first half of 2025 has been marked by a surge in strategic activity across the global healthcare, life sciences, and biotechnology sectors.
R&D Closed and Collaborative: Mergers, acquisitions, and partner... As we head further into H2, a final look back to the summer’s industry mergers and acquisiti
R&D Closed and Collaborative: Mergers, acquisitions, and partner... Summer’s stretch having drawn out a longer return to our round-ups, as the days shorten and we firmly enter autumn, pharmaphorum takes a look back at the industry
R&D Closed and Collaborative: Mergers, acquisitions, and partner... Welcome to a new pharmaphorum round-up.
Market Access A year of major M&A ahead? The previous few years have seen a slowdown in M&A across the industry, as companies take a cautious approach to expansion.
News Chiesi expands rare disease portfolio with Amryt Pharma acqu... Biopharma and healthcare group Chiesi Farmaceutici S.p.A.
News MSD stops trials of BTK inhibitor for blood cancers MSD has stopped development of BTK inhibitor nemtabrutinib, acquired via its $2.7bn takeover of ArQule, after trial results pointed to a safety issue.
Sales & Marketing Sponsored Securing your ROI: Turning post-acquisition integration into... Join Forinnovia and Little Cube Consulting for a webinar on securing post-acquisition ROI.